Latest:
Dr. Kearns on AEs Associated With Surgery in Prostate Cancer
James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
James L. Gulley, MD, PhD
Latest:
Dr Gulley on the Investigation of PRGN-2009 Plus Bintrafusp Alfa in HPV-Associated Cancers
James L. Gulley, MD, PhD, discusses a phase 1 trial of PRGN-2009 alone and in combination with bintrafusp alfa in patients with recurrent and/or metastatic HPV-associated cancers.
James L. Mohler, MD
Latest:
Dr. Mohler on Recommendations for Genetic Testing in Prostate Cancer
James L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.
James Larkin, MD, PhD
Latest:
Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC
James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.
James Larner, MD
Latest:
Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC
James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).
James M. Cleary MD, PhD
Latest:
BRAF-Mutated Colorectal Cancer: Early Frustrations and Future Optimism
This review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.
James Melotek, MD
Latest:
Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer
James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.